DE60139639D1 - Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung - Google Patents

Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung

Info

Publication number
DE60139639D1
DE60139639D1 DE60139639T DE60139639T DE60139639D1 DE 60139639 D1 DE60139639 D1 DE 60139639D1 DE 60139639 T DE60139639 T DE 60139639T DE 60139639 T DE60139639 T DE 60139639T DE 60139639 D1 DE60139639 D1 DE 60139639D1
Authority
DE
Germany
Prior art keywords
substituents
group optionally
substituted
preparation
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139639T
Other languages
English (en)
Inventor
Noritaka Kuroda
Yoshi Nara
Shohei Hashiguchi
Akihiro Tasaka
Masami Kusaka
Masuo Yamaoka
Tomohiro Kaku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60139639D1 publication Critical patent/DE60139639D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DE60139639T 2000-12-08 2001-12-07 Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung Expired - Lifetime DE60139639D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000373868 2000-12-08
PCT/JP2001/010723 WO2002046186A1 (fr) 2000-12-08 2001-12-07 Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation

Publications (1)

Publication Number Publication Date
DE60139639D1 true DE60139639D1 (de) 2009-10-01

Family

ID=18843165

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139639T Expired - Lifetime DE60139639D1 (de) 2000-12-08 2001-12-07 Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung

Country Status (8)

Country Link
US (1) US7067537B2 (de)
EP (1) EP1348706B1 (de)
JP (1) JP2008266349A (de)
AT (1) ATE440096T1 (de)
AU (1) AU2002221080A1 (de)
CA (1) CA2431171A1 (de)
DE (1) DE60139639D1 (de)
WO (1) WO2002046186A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1914244T3 (da) 1999-04-09 2013-07-22 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2004018463A2 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
WO2004099165A2 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
EP1626962B1 (de) * 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamidinhibitoren des p2x7-rezeptors
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
ATE396718T1 (de) * 2003-12-19 2008-06-15 Rigel Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
EP1763353A1 (de) * 2004-06-29 2007-03-21 Warner-Lambert Company LLC KOMBINATIONSTHERAPIEN MIT BENZAMID-HEMMERN DES P2X<SB>7</SB> REZEPTORS
MXPA06014022A (es) * 2004-06-29 2007-02-08 Pfizer Prod Inc Prcedimientos para preparar inhibidores de p2x7.
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US8207196B2 (en) 2007-02-02 2012-06-26 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
EP2220050A2 (de) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoinverbindungen als androgenrezeptormodulatoren
UA108979C2 (uk) * 2008-03-14 2015-07-10 Оцука Фармасьютікал Ко., Лтд. Застосування тетоміласту при лікуванні фіброзу або легеневої емфіземи
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
EA027584B1 (ru) 2011-06-10 2017-08-31 Мерк Патент Гмбх Композиции и способы получения пиримидиновых и пиридиновых соединений с btk ингибирующей активностью
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
SG11201503573WA (en) * 2012-11-16 2015-06-29 Hoffmann La Roche Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
CN111263756B (zh) * 2017-07-11 2023-05-16 赛泰尔治疗公司 Rad51抑制剂
AU2021225921A1 (en) * 2020-02-28 2022-09-22 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821384A (en) * 1972-10-06 1974-06-28 Uniroyal Inc Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same
US4153703A (en) * 1977-06-30 1979-05-08 Uniroyal, Inc. Method of controlling insects and acarids with certain aryl-substituted thiazoles
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
ZA882717B (en) 1987-04-22 1988-10-17 Merrell Dow Pharmaceuticals Inc. 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
WO1992015404A1 (en) 1991-03-01 1992-09-17 S.L. Electrostatic Technology, Inc. Powder coating method for producing circuit board laminae and the like
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
AU668144B2 (en) 1992-03-31 1996-04-26 Btg International Limited 17-substituted steroids useful in cancer treatment
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
PL313769A1 (en) 1993-09-30 1996-07-22 Yamanouchi Pharma Co Ltd Azole derivative and pharmaceutical composition thereof
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
HUP9801158A3 (en) 1995-03-01 1999-11-29 Yamanouchi Pharma Co Ltd Imidazole derivatives and medicinal composition thereof
WO1997000257A1 (fr) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazole fusionnes et composition medicinale les contenant
DE69713285T2 (de) * 1996-02-14 2003-01-02 Aventis Pharmaceuticals Inc., Bridgewater 17-beta-cyclopropyl(amino/oxy)4-aza steroide als testosterone 5-alpha-rectase und c17-20-lyase hemmende verbindungen
CA2250908C (en) * 1996-04-30 2012-03-13 Takeda Chemical Industries, Ltd. Combined use of gnrh agonist and antagonist
AU4298997A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
AU4015497A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
JP2001509166A (ja) 1997-01-28 2001-07-10 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のためのβ▲下３▼作動薬としてのチアゾールベンゼンスルホンアミド
CA2281598A1 (en) * 1997-02-21 1998-08-27 Tetsuya Aono Fused ring compounds, process for producing the same and use thereof
JPH1179993A (ja) * 1997-09-05 1999-03-23 Sumitomo Pharmaceut Co Ltd 免疫抑制剤
DK1028110T3 (da) 1997-10-02 2004-07-19 Daiichi Seiyaku Co Hidtil ukendte dihydronaphthalenforbindelser og fremgangsmåde til fremstilling deraf
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
ATE293102T1 (de) 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
AU774827B2 (en) 1999-03-15 2004-07-08 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
ES2275500T3 (es) 1999-04-23 2007-06-16 Takeda Pharmaceutical Company Limited Compuestos de 5-piridil-1,3-azol, procedimiento para su produccion y uso de los mismos.
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
DE60027034T2 (de) * 1999-10-22 2006-11-09 Takeda Pharmaceutical Co. Ltd. 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
AU2001248820A1 (en) * 2000-04-28 2001-11-12 Shionogi And Co., Ltd. Thiazole and oxazole derivatives
WO2003027101A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors

Also Published As

Publication number Publication date
ATE440096T1 (de) 2009-09-15
EP1348706A4 (de) 2005-08-10
CA2431171A1 (en) 2002-06-13
JP2008266349A (ja) 2008-11-06
AU2002221080A1 (en) 2002-06-18
EP1348706B1 (de) 2009-08-19
WO2002046186A1 (fr) 2002-06-13
EP1348706A1 (de) 2003-10-01
US20040072876A1 (en) 2004-04-15
US7067537B2 (en) 2006-06-27

Similar Documents

Publication Publication Date Title
DE60139639D1 (de) Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
CY1106166T1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf.
ATE334973T1 (de) Chinazolinverbindungen
DE60309829D1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
DE69232022D1 (de) Naphthyridinderivate als Angiotensin-II-Antagonist-Inhibitoren
DE69032414D1 (de) Diphenylmethane derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
NO20073393L (no) [1,2,4]tnazolo [4,3-A] pyridin derivater for behandlingen av hyperproliferative sykdommer
ATE316083T1 (de) Adamantanderivate
HUT59394A (en) Process for producing piperazine derivatives and pharmaceutical compositions comprising same
ATE159514T1 (de) Substituierte aminsäure derivate verwendbar für die behandlung von arteriosclerosis
DE69428142D1 (de) Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
DE60027034D1 (de) 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
HUT72674A (en) Morpholine derivatives and pharmaceutical compositions containing them
ATE214064T1 (de) Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
DK1150974T3 (da) Heterocykliske derivater som inhibitor af faktor Xa
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
HUP9900642A2 (hu) Símaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
ATE233266T1 (de) 8h-(2,3-b)-pyrrolozin-8-one derivate, verfahren zur ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
NO960777L (no) Anvendelse av N-alkylerte 1,4-dihydropyridin dikarboksylsyreestere som medikamenter
JO1697B1 (en) Pyridine derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition